Dasatinib vs imatinib in the treatment of paediatric ALL

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

SABCS 2019 highlights

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma